MOHANE COUMAR S Assistant Professor

Profile Picture

  • Centre for Bioinformatics
  • School of Life Sciences
  • mohane@bicpu.edu.in

Academic Activity

Academic Activity Picture1

Academic Activity Picture2

Educational Qualification (UG,PG & Higher Order)

S.No Degree Subject/Title of thesis University/Board Year of Passing
1 Ph.D Pharmaceutical Sciences Panjab univerisity 2003
2 M.Pharm Pharmaceutical Chemistry Panjab univerisity 1996
3 B.Pharma Pharmacy Kerala University 1994

Area of Specializaion

Computer-aided drug design & Medicinal Chemistry

Awards / Prizes Conferred

S.No Name / Title of the Award Type Name of the Agency conferred the Award Year of the Award Amount for Cash Award

Teaching Experience

S.No Designation Department/Centre Institution
1 Assistant Professor Bioinformatics Pondicherry University

Research Experience

S.No Designation Department/Centre Institution Area of Research
1 Post Doctoral Fellow Division of Biotechnology & Pharmaceutical Research National Health research Institutes, Taiwan New Drug discovery for Cancer and DIabetes
2 Post Doctoral Fellow Department of Chemistry National Tsing Hua Univeristy, Taiwan Drug discovery
3 Research Officer ICMR Centre for Advanced Research Regional Research Laboratory, Jammu, India Herbal Drug Standardization for Clinical Trials
4 Senior Project Fellow ICMR Centre for Advanced Research Regional Research Laboratory, Jammu, India Herbal Drug Pharmacopeia
5 Ph.D candidate and Senior Research Fellow Department of Pharmaceutical Chemistry University Institute of Pharmaceutical Sciences, Panjab University, India New Drug discovery for Cardiovascular Diseases

Industry Experience

S.No Designation Company/Corporate Nature of Work
1 Research Scientist Ranbaxy Research Laboratory, Gurgaon , India Drug discovery research

Contribution towards Innovation

S.No Name of the Work/Contribution Specialization Remarks

Patent Details

S.No Title Status Patent Number Year of Award Type Commercialized Status
1 Fused Multicyclic Compounds as Protein Kinase Inhibitors GRANTED KR101718386B1 2017 INTERNATIONAL NO
2 Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors GRANTED KR101703941B1 2017 INTERNATIONAL NO
3 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED EP2276346B1 2016 INTERNATIONAL NO
4 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED KR101667822B1 2016 INTERNATIONAL NO
5 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED CA2722220C 2016 INTERNATIONAL NO
6 Fused Multicyclic Compounds as Protein Kinase Inhibitors GRANTED US9006252 2015 INTERNATIONAL NO
7 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED AU2009241469 2015 INTERNATIONAL NO
8 Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors GRANTED JP5781934 2015 INTERNATIONAL NO
9 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED JP5502072 2014 INTERNATIONAL NO
10 Fused Multicyclic Compounds as Protein Kinase Inhibitors GRANTED EP 2331530 2013 INTERNATIONAL NO
11 Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors GRANTED US8507502 2013 INTERNATIONAL NO
12 Fused Multicyclic Compounds as Protein Kinase Inhibitors GRANTED TWI400242 2013 INTERNATIONAL NO
13 Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors GRANTED TWI385174 2013 INTERNATIONAL NO
14 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED TWI363627 2012 INTERNATIONAL NO
15 Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors GRANTED US8138194, 2012 INTERNATIONAL NO

Papers Published in UGC Approved Journals

S.No Title Name of the Authors as per the order in Paper Journal Name Volume, Issue & Page Nos. Year Impact Factor
1 Repurposing antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia Phani K Parcha; Sailu Sarvagalla; Cheemala Ashok; S J Sudharshan; Madhu Dyavaiah, Ph.D; Mohane Selvaraj Coumar*; Baskaran Rajasekaran Pharmacological reports 72 2020 2.7
2 Design of a potent anticancer lead inspired by natural products from traditional Indian medicine Hemant Arya, C. Suresh Yadav, Shu-Yu Lin, Safiulla Basha Syed, Sathananthan Kannadasan, Hsing-Pang Hsieh, Sorokhaibam Sureshkumar Singh, Padma Raj Gajurel, and Mohane Selvaraj Coumar* Journal of Biomolecular Structure and Dynamics 38, 3563-3577 . 2020 3.1
3 BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibrobl Tzu-Yu Lin, Hsiu-Han Chan, Shang-Hung Chen, Sailu Sarvagalla, Pai-Sheng Chen, Mohane Selvaraj Coumar, Siao-Muk Cheng, Yung-Chieh Chang, Chun-Hui Lin, Euphemia Leung, and Chun Hei Antonio Cheung Autophagy 16, 1296–1313 2020 11.1
4 Identification of novel quinoline inhibitors for EHMT2/G9a through virtual screening M Ramya Chandar Charles, Arun Mahesh, Shu-YuLin, Hsing-Pang Hsieh, Arunkumar Dhayalan, Mohane Selvaraj Coumar* Biochimie 168, 220-230. 2020 3.2
5 Drug-Like Property Optimization: Discovery of Orally Bioavailable Quinazoline-Based Multi-Targeted Kinase Inhibitors Shu Yu Lin, Chun-Feng Chang, Mohane Selvaraj Coumar, Pei-Yi Chen, Fu-Ming Kuo, Chun-Hwa Chen, Po-Chu Kuo, Mu-Chun Li, Sing-Yi Wang, An-Siou Li, Chin-Yu Lin, Chen-Ming Yang, Teng-Kuang Yeh Bioorganic Chemistry 98, 103689 2020 3.9
6 The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. Yung-Chieh Chang, Sree Karani Kondapuram, Tsung-Han Yang, Safiulla Basha Syed, Siao Muk Cheng, Tzu-Yu Lin, Yi-Chen Lin, Mohane Selvaraj Coumar Jang-Yang Chang, Euphemia Leung, Chun Hei Antonio Cheung Toxicology and Applied Pharmacology 401, 115080 2020 3.4
7 Multi-objective genetic algorithm for de novo drug design (MoGADDrug) R. Vasundhara Devi, S. Siva Sathya, Mohane Selvaraj Coumar Current Computer-Aided Drug Design https://www.eurekaselect.com/182977/article 2020 1.0
8 Investigation of piperine analogs as P-glycoprotein inhibitors with decreased cross-reactivity with CYP3A4 enzyme Safiulla Basha Syed, Shu-Yu Lin, Hemant Arya, I-Hsuan Fu, Teng-Kuang Yeh, Mariasoosai Ramya Chandar Charles, Latha Periyasamy, Hsing-Pang Hsieh, and Mohane Selvaraj Coumar.* Chemical Biology and Drug Design https://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.13758 2020 2.3
9 Design of novel ROCK inhibitors using fragment-based de novo drug design approach. Hemant Arya and Mohane Selvaraj Coumar* J Molecular Modeling 26, 249 2020 1.2
10 Enhanced drug retention, sustained release, and anti-cancer potential of curcumin and indole-curcumin analog-loaded polysorbate 80-stabilizied PLGA na Shamim Akhtar Sufi, Muddasarul Hoda, Sankar Pajaniradje, Sultana Parveen, Selvaraj Mohane Coumar and Rukkumani Rajagopalan International Journal of Pharmaceutics 588, 119738 2020 4.8
11 Multi-objective biofilm algorithm (MOBifi) for de novo drug design with a special focus to anti-diabetic drugs R. Vasundhara Devi, S. Siva Sathya, Mohane Selvaraj Coumar Applied Soft Computing 96, 106655 2020 5.5
12 Survivin - Caspase protein-protein interaction: experimental evidence and computational investigations to decipher the hot spot residues for drug tar Sailu Sarvagalla, Tzu-Yu Lin, Sree Karani Kondapuram, Chun Hei Antonio Cheung, and Mohane Selvaraj Coumar*. Journal of Molecular Strcture 129619 2020 2.7
13 Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics s M Ramya Chander Charles, Hsing-Pang Hsieh, Mohane Selvaraj Coumar* Journal of Biomolecular Structure and Dynamics 37, 10, 2581-2592. 2019 3.1
14 Cloning, expression, and purification of the recombinant pro-apoptotic dominant-negative survivin T34A-C84A protein in Escherichia coli. Shing-Ling Tsai, Yung-Chieh Chang, Sailu Sarvagalla, Shuying Wanga,, Mohane Selvaraj Coumar, Chun Hei Antonio Cheung. Protein Expression and Purification, 160, 73-83 2019 1.4
15 Multi-objective Monkey Algorithm for Drug design R. Vasundhara Devi, S. Siva Sathya, Nilabh Kumar, Mohane Selvaraj Coumar Int. J. Intelligent Systems and Applications 3, 31-41 2019 0
16 Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance Vivek Kumar Singh and Mohane Selvaraj Coumar* Mini Rev Med Chem. 19 (4), 333-345 2019 2.5
17 Insights for the design of protein lysine methyltransferase G9a inhibitors M Ramya Chander Charles, Arunkumar Dhayalan, Hsing-Pang Hsieh, Mohane Selvaraj Coumar* Future Medicinal Chemistry 11,9. 2019 4.1
18 Targeting autophagy with small molecules for cancer therapy Kondapuram Sreekarani, Sailu Sarvagalla, and Mohane Selvaraj Coumar*. J. Cancer Metastasis and Treatment 5, 32 2019 0
19 Can phytochemicals be more specific and efficient at targeting P‑glycoproteins to overcome multi‑drug resistance in cancer cells? In The 150 most Mohane Selvaraj Coumar and Safiulla Basha Syed Cancer Commun 38: 69 2018 3.8
20 Investigations of chemical constituents of clerodendrum colebrookianum in anti-hypertensive drug targets using docking and molecular dynamics simulati Hemant Arya, Safiulla Basha Syed, Sorokhaibam Sureshkumar Singh, Dinakar R. Ampasala and Mohane Selvaraj Coumar*. Interdisciplinary Sciences: Computational Life Sciences 10, 792-804 2018 0.8
21 Impact of genetic variations in HIV-1 TAT on LTR-mediated transcription via TAR RNA interaction: emergence of virulent strains among HIV-1 infected no Larance Ronsard, Nilanjana Ganguli, Vivek Kumar Singh, Kumaravel Mohankumar, Tripti Rai, Subhashree Sridharan, Sankar Pajaniradje, Binod Kumar, Suhnrita Chaudhuri, Mohane Selvaraj Coumar, Vishnampetta Frontiers in Microbiology 8: 706 2017 4.0
22 Ensemble-based virtual screening: identification of potential allosteric inhibitor of BCR-ABL Vivek Kumar Singh and Mohane Selvaraj Coumar*. Journal of Molecular Modeling 23, 218 2017 1.4
23 PRMT7 interacts with ASS1 and citrullinemia mutations disrupt the interaction Mamta Verma, Ramya Chandar Charles. M, Baskar Chakrapani, Mohane Selvaraj Coumar, Gayathri Govindaraju, Arumugam Rajavelu, Sreenivas Chavali & Arunkumar Dhayalan Journal of Molecular Biology 429, 2278-2289 2017 4.6
24 Identification of a novel leukemic-specific splice variant of DNMT3B and its stability Singh P, Sailu S, Palchamy E, Coumar MS, Baluchamy Medical Oncology 34 (8): 145 2017 2.6
25 Reversible testicular toxicity of piperine on male albino rats Gopichand Chinta, Mohane Selvaraj Coumar and Latha Periyasamy Pharmacognosy Magazine 13, S525-S532 2017 1.0
26 Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia. Phanikrishna P, Sailu Sarvagalla, Bindu Madhuri, Sankar Pajaniradje, Vinitha Baskaran, Mohane Selvaraj Coumar, & R. Baskaran. Chemical Biology & Drug Design 90, 596–608 2017 2.4
27 Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Safiulla Basha Syed, Hemant Arya, I-Hsuan Fu, Teng-Kuang Yeh, Latha Periyasamy, Hsing-Pang Hsieh, and Mohane Selvaraj Coumar* Scientific Reports 7, 7972 2017 4.3
28 Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of drugbank database for allosteric bcr-abl inhibitors Vivek Kumar Singh, Hsin-Huei Chang, Ching-Chuan Kuo, Hui-Yi Shiao, Hsing-Pang Hsieh and Mohane Selvaraj Coumar* Journal of Biomolecular Structure and Dynamics 29, 1-16 2017 3.1
29 In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione Shamim Akhtar Sufi, Lakshmi Narayana Adigopula, Safiulla Basha Syed, Victor Mukherjee, Mohane S. Coumar, H. Surya Prakash Rao and Rukkumani Rajagopalan Biomedicine & Pharmacotherapy 85, 389–398 2017 2.8
30 Discovery of BPR1K871 - a quinazoline based multi-kinase inhibitor for the treatment of aml and solid tumors: rational design, synthesis, in vitro and Yung Chang Hsu, Mohane Selvaraj Coumar, Wen-Chieh Wang, Hui-Yi Shiao, Yi-Yu Ke, Wen-Hsing Lin, Ching-Chuan Kuo, Chun-Wei Chang, Fu-Ming Kuo, Pei-Yi Chen, Sing-Yi Wang, An-Siou Li, Chun-Hwa Chen, P Oncotarget 7, 86239-86256 2016 5.2
31 Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug targ Sailu Sarvagalla, Chun Hei Antonio Cheung, Ju-Ya Tsai, Hsing Pang Hsieh and Mohane Selvaraj Coumar* RSC Advances 6, 31947-31959 2016 3.1
32 Therapeutic polymeric nanoparticles and methods of making and using same: a patent evaluation of WO2015036792 Sailu Sarvagalla, Hsing-Pang Hsieh and Mohane Selvaraj Coumar*. Expert opinion in Therapeutic Patents 26 (7), 751-755 2016 4.9
33 P-glycoprotein mediated multidrug resistance reversal by phytochemicals: a review of SAR & future perspective for drug design. Safiulla Basha Syed, Mohane Selvaraj Coumar* Current Topics in Medicinal Chemistry 16(22), 2484-508 2016 2.5
34 Evolutionary algorithms for de novo drug design – a survey. R. Vasundhara Devi, S. Siva Sathya, Mohane Selvaraj Coumar* Applied Soft Computing 27, 543-552 2015 3.5
35 Structural biology insight for the design of sub-type selective aurora kinase inhibitors. Sailu Sarvagalla and Mohane Selvaraj Coumar* Current Cancer Drug Targets 15, 375-393 2015 3.0
36 Piperine: a comprehensive review of pre-clinical and clinical investigations. Gopichand Chinta, Safiulla Basha Syed, Mohane Selvaraj Coumar, Latha Periyasamy Current Bioactive Compounds 11(3), 156-169 2015 NA
37 Identification of ligand efficient, fragment-like hits from an hts library: structure-based virtual screening and docking investigations of 2H- and 3H Sailu Sarvagalla, Vivek Kumar Singh, Yi-Yu Ke, Hui-Yi Shiao, Wen-Hsing Lin, Hsing-Pang Hsieh, John T. A. Hsu, and Mohane Selvaraj Coumar*. Journal of Computer Aided Molecular Design 29, 89-100 2015 3.0
38 In silico and in vitro investigation of the piperine’s male contraceptive effect: docking and molecular dynamics simulation studies in androgen bin Gopichand Chinta, Mariasoosai Ramya Chandar Charles, Ivana Klopčič, Marija Sollner Dolenc, Latha Periyasamy,* and Mohane Selvaraj Coumar* Planta Medica 81, 804-12 2015 2.3
39 Homology modeling of dfg-in fms-like tyrosine kinase (FLT3) and structure-based virtual screening for inhibitor identification. Yi-Yu Ke, Vivek Kumar Singh, Mohane Selvaraj Coumar, Yung Chang Hsu, WenChieh Wang, Jen-Shin Song, Chun-Hwa Chen, Wen-Hsing Lin, Szu-Huei Wu, John T. A. Hsu, Chuan Shih & Hsing-Pang Hsieh Scientific Reports 5:11702 2015 4.3
40 BDMC-A, an analog of curcumin, inhibits markers of invasion, angiogenesis, and metastasis in breast cancer cells via NF-ΚB pathway- a comparative stu Kumaravel Mohankumar, Subhashree Sridharan, Sankar Pajaniradje, Vivek Kumar Singh, Larance Ronsard, Akhil C. Banerjea, Dinesh Babu Somasundaram, Mohane Selvaraj Coumar, Latha Periyasamy, Rukkumani Raj Biomedicine & Pharmacotherapy 74, 178-186 2015 2.8
41 Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-13) Chun Hei Antonio Cheung, Sailu Sarvagalla, Jane Ying-Chieh Lee, Yi-Chun Huang, Mohane Selvaraj Coumar* Expert opinion in Therapeutic Patents 24 (9), 1021-1038 2014 4.9
42 Mechanism of apoptotic induction in human breast cancer cell, mcf-7, by an analog of curcumin in comparison with curcumin - an in vitro and in silico Kumaravel Mohankumar, Sankar Pajaniradje, Subhashree Sridharan, Vivek Kumar Singh, Larance Ronsard, Akhil C Banerjea, Chellakkan S Benson, Mohane Selvaraj Coumar, Rukkumani Rajagopalan. Chemico-Biolgical Interactions 210, 51-63. 2014 3.1
43 Virtual screening of traditional chinese medicine (TCM) database: identification of fragment-like lead molecules for filariasis target asparaginyl-trn Hemant Arya and Mohane Selvaraj Coumar*. Journal of Molecular Modeling 20, 2266 2014 1.4
44 Ligand efficiency based approach for efficient virtual screening of compound libraries Yi-Yu Ke, Mohane Selvaraj Coumar, Hui-Yi Shiao, Wen-Chieh Wang, Chieh-Wen Chen, Jen-Shin Song, Chun-Hwa Chen, Wen-Hsing Lin, Szu-Huei Wu, John T. A. Hsu, Chung-Ming Chang and Hsing-Pang Hsieh. European Journal of Medicinal Chemistry 83, 226-235. 2014 4.5
45 Apoptotic induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through extrinsic and intrinsic pathways. Kumaravel Mohankumar, Sankar Pajaniradje, Subhashree Sridharan, Vivek Kumar Singh, Larance Ronsard, Akhil C Banerjea, Chellakkan S Benson, Mohane Selvaraj Coumar, Latha Periyasamy, Rajagopalan Rukkuma Cellular Oncology 37,439-454 2014 3.8
46 Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor. Hui-Yi Shiao, Mohane Selvaraj Coumar, Chun-Wei Chang, Yi-Yu Ke, Ya-Hui Chi, Chang-Ying Chu, Hsu-Yi Sun, Chun-Hwa Chen, Wen-Hsing Lin, Ka-Shu Fung, Po-Chu Kuo, Chin-Ting Huang, Kai-Yen Chang, Cheng-Tai Journal of Medicinal Chemistry 56, 5247-5260 2013 6.3
47 Protein kinase inhibitor design by targeting the ASP-PHE-GLY (DFG) motif: the role of the dfg motif in the design of epidermal growth factor receptor Yi-Hui Peng, Hui-Yi Shiao, Chih-Hsiang Tu, Pang-Min Liu, John Tsu-An Hsu, Prashanth Kumar Amancha, Jian-Sung Wu, Mohane Selvaraj Coumar, Chun-Hwa Chen, Sing-Yi Wang, Wen-Hsing Lin, Hsu-Yi Sun, Yu-Shen Journal of Medicinal Chemistry 56, 3889−3903 2013 6.3
48 Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules Jiun-Ming Wu, Chiung-Tong Chen, Mohane Selvaraj Coumar, Wen-Hsin Lin, Zi-Jie Chen, John T.-A. Hsu, Yi-Hui Peng, Hui-Yi Shiao, Wen-Hsing Lin, Chang-Ying Chu, Jian-Sung Wu, Chih-Tsung Lin, Ching-Pin Proceedings of the National Academy of Sciences of U S A 110, E1779-E1787 2013 9.7
49 3D-QSAR assisted drug design: identification of a potent quinazoline based aurora kinase inhibitor Yi-Yu Ke, Hui-Yi Shiao, Yung Chang Hsu, Chang-Ying Chu, Wen-Chieh Wang, Yen-Chun Lee, Wen-Hsing Lin, Chun-Hwa Chen, John T. A. Hsu, Chun-Wei Chang, Cheng-Wei Lin, Teng-Kuang Yeh, Yu-Sheng Chao, Mo ChemMedChem. 8, 136-148 2013 3.2
50 Treat cancers by targeting survivin: just a dream or future reality? Mohane Selvaraj Coumar, Fang-Ying Tsai, Jagat Rakesh Kanwar, Sailu Sarvagalla, Chun Hei Antonio Cheung. Cancer Treatment Reviews 39, 802-811 2013 8.6
51 Anti-influenza drug discovery: identification of orally bioavailable quinoline derivative through activity and property guided lead optimization Jiann-Yih Yeh, Mohane Selvaraj Coumar, Hui-Yi Shiao, Ta-Jen Lin, Yen-Chun Lee, Hui-Chen Hung, Shengkai Ko, Fu-Ming Kuo, Ming-Yu Fang, Yu-Lin Huang, John T. A. Hsu, Teng-Kuang Yeh, Shin-Ru Shih ChemMedChem. 7, 1546-1550 2012 3.2

Papers Published in Peer Reviewed Journals

S.No Title Name of the Authors as per the order in Paper Journal Name Volume, Issue & Page Nos. Year Impact Factor

Papers Published in Conference Proceedings

S.No Title Name of the Authors as per the order in Paper Details of Conference Publication Page Nos. Year
1 GAMOL: genetic algorithm based de novo molecule generator R. Vasundhara Devi, S. Siva Sathya and Mohane Selvaraj Coumar* Int. Conf. on Adv. in Comp., Comm., and Inf. Sci. (ACCIS-14). TKM College of Engineering, Kollam, Kerala, India, June 26-28th 259-265 2014

Books

S.No Title of the Book Name of the Authors as per the order in Book Publisher Year ISBN No.

Chapters in Books

S.No Title of the Chapters Name of the Authors Title of the Book Publisher Year ISBN No.
1 Resources for docking–based virtual screening Sailu Sarvagalla, Sree Karani Kondapuram, R. Vasundhara Devi and Mohane Selvaraj Coumar* Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications Academic Press 2021 9780128223123
2 Docking–based virtual screening using PyRx tool: autophagy target Vps34 as a case study 98. Sree Karani Kondapuram, Sailu Sarvagalla, and Mohane Selvaraj Coumar* Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications Academic Press 2021 9780128223123
3 An Overview of Computational Methods, Tools, Servers and Databases for Drug Repurposing Sailu Sarvagalla, Safiulla Basha Syed and Mohane Selvaraj Coumar* In Silico Drug Design: Repurposing Techniques and Methodologies Academic Press 2019 1522503625
4 Protein-protein interactions (PPIs) an alternative to targeting the atp binding site of kinase: in silico approach to identify ppi inhibitors Sailu Sarvagalla and Mohane Selvaraj Coumar* Applied Case Studies and Solutions in Molecular Docking-Based Drug Design IGI Global 2016 1522503625

Edited Books

S.No Title of the Book Name of the Authors as per the order in Book Publisher Year ISBN No.
1 Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications S. Mohane Coumar Academic Press 2021 9780128223123

Ongoing Projects

S.No Title of the Project Sponsored By Period Sanctioned Amount(Rs. Lakh) Year

Ongoing Consultancy Works

S.No Title of the Consultancy Work Sponsored By Period Sanctioned Amount(Rs. Lakh) Year

Completed Projects

S.No Title of the Project Sponsored By Period Sanctioned Amount(Rs. Lakh) Year
1 Computational and biochemical approaches for in-silico screening and discovery of drug-like leads: Anti-diabetic and anti-hypertensive compounds from Clerodendrum spp. occurring in North East India DBT 2012- 2015 11.83 Lahks 2015
2 Design and discovery of aurora kinase inhibitors as anti-cancer drugs: Application of computer aided drug design DST 2012- 2015 24.30 Lakhs 2015
3 Targeted anti-cancer agents: Structural Bioinformatics approach to the Design & Development of allosteric Kinase inhibitors UGC 2012- 2015 10.10 Lahks 2015

Completed Consultancy Works

S.No Title of the Consultancy Work Sponsored By Period Sanctioned Amount(Rs. Lakh) Year

Career Guidance Offered to students

S.No Name of the Scheme No. of Students Competitive Examinations/ Career Counseling No. of Students Passed No. of Students Placed

List of capability enhancement such as Soft skill development, Remedial coaching, Language lab,
Bridge courses, Yoga, Meditation, Personal Counselling and Mentoring etc.,

S.No Name of the Programme/Scheme Date of Implementation No. of Students Enrolled Agencies Involved

Research Guidance - PG

S.No Year Degree No. of Students Awarded Department/Centre

Research Guidance - Ph.D

S.No Student Name Registration Date Registration No. Thesis Title Thesis Submitted Status Thesis Submitted Date Vivavoce Completed Status Date Awarded
1 Safi Bhasha syed 29-11-2012 PU/CE/E9/PHD/2012-13/ Design and Development of Piperine Based P-glycoprotein (P-gp) Inhibitors to Overcome Drug Resistance in Cancer YES 08-02-2019 YES 30-09-2019
2 Sarvagalla Sailu 26-08-2011 PU/CE/E9/PHD/2011-12/ Targeting the cell cycle for cancer treatment: Computational approaches for the inhibition of Aurora kinase and Survivin YES 06-04-2017 YES 12-04-2018
3 BRINDANGNANAM P 25-07-2018 1800104004 Ant-bacterial drug design NO NO
4 Vivek Kumar Singh 24-07-2012 PU/CE/E9/PHD/2012-13/ TARGETED ANTICANCER AGENTS: STRUCTURAL BIOINFORMATICS APPROACH TO OVERCOME IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA YES 18-12-2017 YES 24-08-2018
5 Kondapuram Sree Karani 23-07-2018 1800104006 Autophagy targeted drug discovery NO NO
6 Hemant Arya 09-05-2013 PU/CE/E9/PHD/2012-13/ Bio-prospecting of natural products for the development of drug-like leads: integrated computational and experimental approaches YES 10-09-2018 YES 12-04-2019
7 BIKASHITA KALITA 05-08-2019 1900104002 Metastatic cancer NO NO
8 Ramya Chandar Charles 01-08-2013 PU/CE/E9/PHD/2013-14/ Computational Investigations of G9a Lysine Methyltransferase for the Design and Discovery of Novel Inhibitors YES 22-07-2019 YES 10-07-2020

Research Guidance - Post Doctoral

S.No Scholar Name Designation Funding Agency Fellowship Title Year of Joining Year of Completion

Financial assistance availed to attend conferences / workshops and to pay membership fee
of professional bodies during the year

S.No Conference/ workshop attended for which financial support provided Professional body for which membership fee is provided Amount of Support Place From Date To Date Year

E-Lecture Details

S.No E-Lecture Title Development of e-content/e-learning/delivering Member of Editorial Bodies Reviewer/Referee of
Content/Module Title Institution/Platform Year Weblink

Details of Online Education Conducted

S.No Nature of Online Course No. of Sessions Target Group Date

Invited Talks in Conference/Seminar/Workshop/Training Programme

S.No Title of the Paper Conferences/Seminar/Workshop/Training Programme Organized by Whether International / National / State / Regional / College or University Level From To Year
1 Anti-cancer drug development: Computer-aided drug design (CADD) for lead identification and optimiza Computational Approaches to Drug Discovery Bioinformatics Centre, Pondicherry University National 13/12/2017 19/12/2017 2017
2 Drug Repurposing: Targeting Allosteric site of Bcr-Abl for the treatment of Chronic Myeloid Leukemia National Seminar on Drug Discovery and Cancer Therapy Department of Biochemistry and Molecular Biology, Pondicherry University National 25/02/2016 26/02/2016 2016
3 Computer-aided drug design: Design of anti-filarial agent from natural products Seminar on Genomics & Proteomics of Disease Vectors and Pathogens Vector Control Research Centre, Pondicherry National 03/11/2015 03/11/2015 2015
4 Hit to Lead Evolution: Aurora kinase Inhibitor Development Drug Design and Industrial Applications Bioinformatics Centre, Pondicherry University National 09/03/2012 09/03/2012 2012

Conferences/Seminars Organized

S.No Title of the Programme Sponsors Venue & Duration Whether International / National / State / Regional / College or University Level From To Year

Workshop Organized

S.No Title of the Programme Sponsors Venue & Duration Whether International / National / State / Regional / College or University Level From To Year

Administrative Responsibilities in the Government and Quasi Government Agencies

S.No Name of the Position Agency/Organisation Duration Nature of Duties

Affiliation in Academic Bodies/Societies

S.No Name of the Body/Society Nature of Affiliation Year
1 American Chemical Society Member (Three years) 2015
2 Indian Pharmaceutical Association Life member 2012
3 Indian Science Congress Association Life member 2012

Participation & Extension Activities (Academic/Administraion)

S.No Name of the Position (Head, Dean, Co-ordinator, Director, etc.,) Duration Nature of Dutites

Participation & Extension Activities (Co-Curricular)

S.No Name of the Position (NSS, NCC, Warden etc.,) Duration Nature of Dutites

Collaboration with Institution/Industry

S.No Collaborator Name Designation Institution/Industry Type Nature of Collaboration Period of Collaboration Visits to Collaborating
Institution / Industry
Details of Collaborative Research/Teaching
From Date To Date From Date To Date

Faculty Development Programme Attended (Orientation, Refresher, other Short Term Course during the year)

S.No Title of the FDP Organiser Venue Duration From Date To Date Year

Details of Executive Development Prog/Management Development Prog. conducted

S.No Name of the Programme No. of Participants Venue Duration From Date To Date Year Revenue Generated

Participation in IMPESS, IMPRINT, SPARC, STARS, LEAP Programme etc and DSF Funding Programme

S.No IMPRESS/IMPRINT/SPARC/STARS/LEAP/Others Place From Date To Date Year

Enrolment under ARPIT Programme

S.No Name of the Programme Period of the Programme
From Date To Date